Your browser doesn't support javascript.
loading
Overall survival with cetuximab every-2-weeks versus standard once-weekly administration schedule for first-line treatment of RAS wild-type metastatic colorectal cancer in patients with left- and right-sided primary tumour location.
Kasper, Stefan; Foch, Caroline; Esser, Regina; Lamy, Francois-Xavier; Zhang, Aimar; Cheng, Ann-Lii; Rouyer, Magali; Brodowicz, Thomas; Zielinski, Christoph.
Afiliação
  • Kasper S; West German Cancer Centre, University Hospital Essen, University of Duisburg-Essen, Germany. Electronic address: stefan.kasper@uk-essen.de.
  • Foch C; Merck Healthcare KGaA, Darmstadt, Germany.
  • Esser R; Merck Healthcare KGaA, Darmstadt, Germany.
  • Lamy FX; Merck Healthcare KGaA, Darmstadt, Germany.
  • Zhang A; Merck Serono (Beijing) Pharmaceutical R&D Co., Ltd, Beijing, China.
  • Cheng AL; National Taiwan University Cancer Center, Taipei, Taiwan.
  • Rouyer M; Bordeaux PharmacoEpi, INSERM CIC1401, University of Bordeaux, Bordeaux, France.
  • Brodowicz T; Internal Medicine, Vienna General Hospital and Medical University of Vienna, Austria.
  • Zielinski C; Comprehensive Cancer Centre, Vienna General Hospital and Medical University of Vienna, Austria.
Eur J Cancer ; 180: 85-88, 2023 02.
Article em En | MEDLINE | ID: mdl-36563490
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Retais / Neoplasias Colorretais / Neoplasias do Colo / Antineoplásicos Imunológicos Limite: Humans Idioma: En Revista: Eur J Cancer Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Retais / Neoplasias Colorretais / Neoplasias do Colo / Antineoplásicos Imunológicos Limite: Humans Idioma: En Revista: Eur J Cancer Ano de publicação: 2023 Tipo de documento: Article